Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Ibrx save search
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 1.27%
H: 0.31%
C: -2.3%
first vaccine cancer trial
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Published: 2024-02-05 (Crawled : 14:30) - immunitybio.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: -1.93%
H: 1.35%
C: -0.49%
favorable bladder cancer trial plus study
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
Published: 2023-04-25 (Crawled : 13:00) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.0%
H: 4.51%
C: -3.69%
cancer trial plus study
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
Published: 2023-01-19 (Crawled : 14:20) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: -1.1%
H: 1.11%
C: 0.22%
fda trial presentation asco update cancer pancreatic
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight
Published: 2022-08-23 (Crawled : 16:00) - prnewswire.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.27%
H: 6.27%
C: 4.0%
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 0.64%
H: 0.32%
C: -0.63%
TARA | $2.62 -4.73% -4.96% 210K
|
Health Technology
|
| O: -0.38%
H: 3.83%
C: 1.73%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.49%
H: 0.36%
C: -0.33%
companies trial bladder cancer
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.17%
H: 0.0%
C: 0.0%
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 14.42%
H: 1.88%
C: -4.29%
trial cancer pancreatic bladder
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer
Published: 2022-04-25 (Crawled : 13:20) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: -3.12%
H: 2.86%
C: 0.0%
trial cancer enroll
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.4%
H: 0.0%
C: -0.58%
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: -1.27%
H: 0.0%
C: 0.0%
phase 2 trial disease media asco cancer pancreatic
ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 1.53%
H: 1.2%
C: -2.41%
AMRS | $0.05 -21.88% -16.36% 47M
|
Process Industries
|
| O: -2.79%
H: 1.93%
C: -3.72%
als bladder cancer trials trial covid cel clinical trials cancer vaccine phase 3 merge t-cell bladder
ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
Published: 2021-10-19 (Crawled : 13:15) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.9%
H: 2.89%
C: 1.78%
disease bladder cancer cancer trial bladder
National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
Published: 2021-10-04 (Crawled : 13:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 1.31%
H: 2.69%
C: -1.89%
therapy cancer trial keytruda
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
Published: 2021-09-13 (Crawled : 13:00) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.81%
H: 3.11%
C: -2.01%
media phase 2 phase 2/3 positive cancer trial response bladder
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
Published: 2021-09-01 (Crawled : 13:00) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.97%
H: 3.13%
C: 2.7%
presentation phase 2 phase 2/3 results cancer trial trial results bladder
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.28%
H: 4.22%
C: 3.49%
disease phase 2 phase 2/3 results trial
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.61%
H: 1.47%
C: -3.12%
phase 2 results cancer trial pancreatic pancreas
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
Published: 2021-07-14 (Crawled : 13:15) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.77%
H: 1.35%
C: -5.32%
covid phase 1 vaccine trial t-cell authorized africa
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
Published: 2021-05-25 (Crawled : 13:15) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 2.23%
H: 2.37%
C: -1.93%
covid nasal spray test vaccine trial approval t-cell africa
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
Published: 2021-05-17 (Crawled : 13:15) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 4.63%
H: 9.4%
C: 4.8%
fda cryo solid tumors trial authorized
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.